Currently Viewing:
Patient-Centered Oncology Care
Oncologists Can Save Oncology If They Take Ownership of Costs, Kolodziej Says
November 17, 2017
Navigators Offer Touch Points on Patients' Cancer Journey
November 18, 2017
Documenting When a Patient Falls Outside a Recommended Pathway
November 20, 2017
Ian Manners: Addressing Financial Toxicity for Patients
November 29, 2017
The Importance of Teamwork in Oncology Care Transitions
November 30, 2017
Dr Brenton Fargnoli Highlights How Practices Can Prepare for Downside Risk
December 15, 2017
Kathleen Lokay: Clinical Pathways Can Prevent Prior Authorization Delays
December 24, 2017
Torrie Fields: Data Collection Takes the Guesswork Out of Care
January 01, 2018
Kathleen Lokay on How Data Generation Informs Clinical Pathways
January 16, 2018
Dr Brenton Fargnoli Discusses the Creation of a Learning Health System
January 25, 2018
Kathleen Lokay on Educating Patients on Treatment Options
January 28, 2018
Dr Brenton Fargnoli Explains How Quality Measurement Benchmarks Drive Action
February 09, 2018
Jason Harris Discusses the Importance of Real-World Evidence
February 11, 2018
Kathleen Lokay: Implementing Value in Clinical Pathways
February 13, 2018
Dr Brenton Fargnoli on Fixing Issues Physicians Have With EHRs
February 18, 2018
Jason Harris: Improving Patient Understanding and Promoting High-Value Care
March 02, 2018
Dr Thomas Graf on the Impact of New Therapies in Oncology
March 12, 2018
Ian Manners Explains the Impact of Patient Financial Assistance Programs
March 17, 2018
Jason Harris Highlights National Health Council's Recommendations on Real-World Evidence
March 18, 2018
Currently Reading
Dr Thomas Graf: How the Impact of Novel Therapies Varies Among Stakeholders
March 22, 2018
Kathleen Lokay: Incorporating the Latest Research and Supporting Physicians
April 05, 2018
Dr Thomas Graf Discusses the Effect of Novel Therapies on Private Coverage
April 06, 2018
Torrie Fields: Collecting and Using Data Can Better Inform a Patient
April 12, 2018
Dr Stacey McCullough Discusses Teamwork and Collaboration in Oncology
April 13, 2018

Dr Thomas Graf: How the Impact of Novel Therapies Varies Among Stakeholders

Each stakeholder (employers, patients, family members, physicians, payers) values the impact of novel therapies differently, said Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey.


Each stakeholder (employers, patients, family members, physicians, payers) values the impact of novel therapies differently, said Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey.

Transcript

How does the impact of novel therapies vary between different stakeholders?

This is really interesting. For patients, it’s wonderful. We have treatments that are revolutionary, that can cure or dramatically improve the survival outcomes for diseases that really had no good options. The challenges though, they come with significant side effects. For some of them, you actually have to be hospitalized in the intensive care unit when you’re given the drug. That gives you some idea the danger associated with it. Even a successful therapy is a little bit challenging. From a payer perspective or provider perspective, understanding that risk to the patients and the members, understanding that impact of the cost, is a real challenge.

The other piece that I think most people haven’t really thought about is as we think about value in healthcare. Each stakeholder values it differently: employers, patients, family members, physicians, payers. But the biggest challenge is the time horizon that each of those recognize their value. For patients, the time horizon is obviously their life, they're open to measurement on and ongoing fashion. For employers, perhaps the time horizon that’s relevant is the time someone’s an employee. So, amortizing that half a million-dollar dose drug across the employed time makes a little more sense. Theoretically, as an insurance company, you’d value someone just for the time that they’re an insured member, which is a real challenge in these situations, because they need the treatment now, it’s gonna be very expensive now. In a year or two, as you start to break even on that member, of course you wouldn’t with these new therapies but conceptually, they may very well be insured somewhere else, so figuring out how to get that cost fare across the system, it is a real challenge. There’s no good answers yet.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up